case_images: PMC7901487_01
case_images: Tumor responses after neoadjuvant therapy. (A) Timeline of disease status and corresponding treatment regimens. W, week. (B) Tumor lesion of pre- and post-neoadjuvant therapy for three patients.
case_images: fonc-10-554040-g001.jpg
case_images: PMC7901487_02_fonc-10-554040-g001.jpg
case_images: f1
case_images: Figure 1B ).
case_images: PMC7901487_02
case_images: Tumor responses after neoadjuvant therapy. (A) Timeline of disease status and corresponding treatment regimens. W, week. (B) Tumor lesion of pre- and post-neoadjuvant therapy for three patients.
case_images: fonc-10-554040-g001.jpg
case_images: PMC7901487_02_fonc-10-554040-g001.jpg
case_images: f1
case_images: Figure 1B ).
case_images: PMC7901487_03
case_images: Biomarker findings of the tumor tissue samples. PD-L1, CD8+ T cells, NK cells, and TAMs (tumor-associated macrophages) of pre- and post-neoadjuvant therapy for patient 1 (A) and patient 2 (B). Original magnification x200.
case_images: fonc-10-554040-g002.jpg
case_images: PMC7901487_03_fonc-10-554040-g002.jpg
case_images: f2
case_images: Pre- and post-neoadjuvant therapy immune microenvironment biomarkers were assessed in two patients (patient 1 and patient 2) with adequate tumor tissues (biopsy samples and surgical samples) ( Figure 2 ).